Advertisement
Evotec, Novo Nordisk Roll Out LAB EN To Accelerate Translation In Cardiometabolic Diseases
(RTTNews) - Evotec SE (EVO, EVOTF.PK) and Novo Nordisk A/S (NVO) announced Tuesday a translational drug discovery accelerator called LAB eN, which aims to nurture early research from academic institutions into novel therapeutics.
LAB eN is a unique engagement model that combines Evotec's multimodality drug discovery and pre-clinical development capabilities with Novo Nordisk's therapeutic, clinical, and commercial expertise.
LAB eN will focus on addressing unmet need in cardiometabolic diseases as well as rare blood and rare endocrine disorders.
LAB eN has already signed on four academic institutions to participate: Harvard University, Mass General Brigham, Yale University, and Beth Israel Deaconess Medical Center.
read more
Novo Nordisk Stock Climbs On Higher Q1 Results; Cuts FY25 Outlook
Shares of Novo Nordisk A/S were gaining around 6 percent in Denmark as well as around 7 percent in the pre-market activity on the NYSE, after the Danish drug major reported Wednesday higher profit and sales in its first quarter, mainly reflecting improved results of its blockbuster weight loss drug Wegovy. Meanwhile, the company trimmed fiscal 2025 outlook for sales and operating profit growth...
RTTNews
|
5天前
Novo Nordisk Plans $4.1 Bln NC Facility To Boost Obesity Drug Supply
Danish drug maker Novo Nordisk announced its plans to invest $4.1 billion or about 27 billion Danish kroner to build a new manufacturing plant in Clayton, North Carolina with a view to expanding its manufacturing capacity in the United States. In the new plant, the company plans to produce current and future injectable treatments for people with obesity and other serious chronic diseases.
RTTNews
|
322天前
Novo Nordisk Says FLOW Trial Achieves Primary Endpoint
Novo Nordisk A/S (NVO) announced Tuesday the headline results from the kidney outcomes trial FLOW. The announcement follows the decision to stop the trial early due to efficacy.
RTTNews
|
433天前
Novo Nordisk Slashes US List Prices Of Several Insulin Products By Up To 75%
Healthcare company Novo Nordisk Inc. (NVO) announced Tuesday it is lowering the U.S. list prices of several pre-filled insulin pens and vials by up to 75% for people living with type 1 and type 2 diabetes.
RTTNews
|
790天前
Additional Support Expected For Thai Stock Market
Ahead of Monday's holiday for Wesak Day, the Thai stock market had alternated between positive and negative finishes through the previous four trading days since the end of the five-day winning streak in which it had advanced more than 50 points or 4.3 percent. The Stock Exchange of Thailand now sits just above the 1,210-point plateau and it's got a strong lead for Tuesday's trade.
RTTNews
|
30分鐘前
Japanese Market Sharply Higher
The Japanese stock market is trading sharply higher on Tuesday, extending the gains in the previous three sessions, following the broadly positive cues from Wall Street overnight, with the Nikkei 225 moving above the 38,300 level, with gains across all sectors led by strong gains in technology and financial stocks.
RTTNews
|
34分鐘前
Overbought Hang Seng Nonetheless Called Higher
The Hong Kong stock market has tracked higher in eight straight sessions, soaring almost 1,600 points or 7.1 percent along the way. The Hang Seng Index now sits just beneath the 23,550-point plateau and it's expected to at least open in positive territory on Tuesday.
RTTNews
|
45分鐘前
Australian Market Significantly Higher
The Australian stock market is trading significantly higher on Tuesday, extending the gains in the previous four sessions, following the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving up to near the 8,300 level, with gains across most sectors led by Technology and energy stocks. Gold stocks were the only weak spot.
RTTNews
|
56分鐘前
